+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Prevalence and Outcomes of Head and Neck versus Non-Head and Neck Second Primary Malignancies in Head and Neck Squamous Cell Carcinoma: An Analysis of the Surveillance, Epidemiology, and End Results Database



Prevalence and Outcomes of Head and Neck versus Non-Head and Neck Second Primary Malignancies in Head and Neck Squamous Cell Carcinoma: An Analysis of the Surveillance, Epidemiology, and End Results Database



Orl; Journal for Oto-Rhino-Laryngology and its Related Specialties 78(2): 61-69



Patients with head and neck squamous cell carcinoma (HNSCC) are at risk for second primary malignancies (SPMs). The prevalence, distribution, and patient survival in head and neck versus non-head and neck SPMs are not fully elucidated. The objective of this study was to quantify the rate of SPMs in patients with HNSCC. This is a population-based cohort study using the Surveillance, Epidemiology, and End Results (SEER) database. Prevalence and location of SPMs, and survival data were analyzed. There were 58,363 HNSCC patients, and the prevalence of HNSCC and non-HNSCC SPMs was 3.0% (1,746) and 8.8% (5,109), respectively. Overall survival (OS) was higher in patients with HNSCC SPMs compared to non-HNSCC SPMs (p < 0.001), with no difference in disease-specific survival. Patients with SPMs in the lung and esophagus had a worse OS (p < 0.001), and patients with SPMs in the prostate and breast had a better OS (p < 0.001). In HNSCC patients who develop SPMs, nearly 75% are non-HNSCC SPMs. Patients with non-HNSCC SPMs have a lower OS. Future clinical practice guidelines should take the risks and locations of SPM development into consideration for screening.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 058613464

Download citation: RISBibTeXText

PMID: 26910465

DOI: 10.1159/000443768


Related references

Tumor Biomarker Association With Clinical Outcomes in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) Patients (Pts) Treated With Afatinib Versus Methotrexate (MTX): LUX-Head & Neck 1 (LHN1). International Journal of Radiation Oncology*biology*physics 94(4): 868-869, 2016

Afatinib versus methotrexate in older patients with second-line recurrent and/or metastatic head and neck squamous cell carcinoma: subgroup analysis of the LUX-Head & Neck 1 trial. Annals of Oncology 27(8): 1585-1593, 2016

A survey on pulmonary screening practices among otolaryngology-head & neck surgeons across Canada in the post treatment surveillance of head and neck squamous cell carcinoma. JournalofOtolaryngology-HeadandNeckSurgery44:5, 2015

Sentinel node in head and neck cancer: use of size criterion to upstage the no neck in head and neck squamous cell carcinoma. Head and Neck 29(2): 95, 2007

The effect of local-regional control on distant metastatic dissemination in carcinoma of the head and neck: results of an analysis from the RTOG head and neck database. International Journal of Radiation Oncology Biology Physics 21(3): 549-556, 1991

Cervical neck dissection for complete responders in head-and-neck: a utilitarian ideal? In regard to Thariat et al "Prediction of neck dissection requirement after definitive radiotherapy for head-and-neck squamous cell carcinoma." (Int J Radiat Oncol Biol Phys 2012;82:e367-e374). International Journal of Radiation Oncology, Biology, Physics 83(3): 768-768, 2012

Health-related quality of life before and after head and neck squamous cell carcinoma: Analysis of the Surveillance, Epidemiology, and End Results-Medicare Health Outcomes Survey linkage. Cancer 122(12): 1861-1870, 2016

Reduced incidence of second head and neck cancers in patients treated with external beam radiotherapy for squatnous cell carcinoma of the head and neck: A SEER database analysis. 2007

Patterns of care in older patients with squamous cell carcinoma of the head and neck: a surveillance, epidemiology, and end results-medicare analysis. Journal of Geriatric Oncology 4(3): 262-270, 2013

Outcomes after primary chemoradiotherapy for N3 (>6 cm) head and neck squamous cell carcinoma after an FDG-PET--guided neck management policy. Head and Neck 36(8): 1200-1206, 2014

Rationale and design of LUX-Head & Neck 1: a randomised, Phase III trial of afatinib versus methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma who progressed after platinum-based therapy. Bmc Cancer 14: 473, 2014

Results of selective neck dissection in the primary management of head and neck squamous cell carcinoma. European Archives of Oto-Rhino-Laryngology 266(3): 437-443, 2009

339TiPphase Iii study of afatinib vs placebo as adjuvant therapy after chemo-radiotherapy (Crt) in primary unresected patients with locoregionally advanced (La) head and neck squamous cell carcinoma (Hnscc) in Asia: Lux-Head & Neck 4 (Lux-H&N4). Annals of Oncology 26(Suppl 9): ix100.1-ix100, 2015

Regional Neck Control in Head and Neck Squamous Cell Carcinoma with Positive Neck Disease Treated with Primary Chemoradiation. Journal of Oral and Maxillofacial Surgery 75(10): E330-E331, 2017

Outcomes of head and neck squamous cell carcinoma patients with N3 neck disease treated primarily with chemoradiation versus surgical resection. Laryngoscope 121(9): 1881-1887, 2011